Jinyu Bio-technology Co., Ltd. (SHA:600201)

Market Cap	15.25B +111.1%
Revenue (ttm)	1.33B -1.7%
Net Income	100.76M -38.9%
EPS	0.10 -35.5%
Shares Out	1.09B
PE Ratio	145.30
Forward PE	82.12
Dividend	0.03 (0.21%)
Ex-Dividend Date	Jun 26, 2025

Volume	21,857,680
Average Volume	28,888,864
Open	13.54
Previous Close	13.66
Day's Range	13.50 - 14.14
52-Week Range	6.50 - 19.00
Beta	0.93
RSI	41.21
Earnings Date	Apr 23, 2026

About Jinyu Bio-technology

Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies ther...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,740
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600201

Financial Performance

In 2024, Jinyu Bio-technology's revenue was 1.26 billion, a decrease of -21.45% compared to the previous year's 1.60 billion. Earnings were 108.99 million, a decrease of -61.57%.